focus -WSS

focus

author：leisure time 2025-09-30 17:27:30 - browse：4

Golden brain and DNA spiral illustration. -- biotech coverage from STAT — Adobe

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.

Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and sovereign wealth fund Alaska Permanent Fund Corp. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.

Kenai — pronounced key-nigh — is developing therapies that use induced pluripotent stem cells, or iPSCs. These highly versatile organisms are derived from skin or blood cells and can be transformed into any type of cell. In Parkinson’s, the idea is that these cells would replace damaged neurons.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Lilly’s weekly insulin works as well as daily products, new studies show

entertainment

WSS

Abbott's new stent may help patients with peripheral artery disease

Texas Department of Public Safety speaks out on migrant abuse allegations

Ripples from Flovent's discontinuation is killing children with asthma

7 more heat

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Ripples from Flovent's discontinuation is killing children with asthma

hotspot

focus

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

Ripples from Flovent's discontinuation is killing children with asthma

Medical leaders decry Supreme Court decision on affirmative action

STAT series 'Denied by AI' wins major journalism prizes

Medical leaders decry Supreme Court decision on affirmative action

Abbott's new stent may help patients with peripheral artery disease

Medical leaders decry Supreme Court decision on affirmative action

Abbott's new stent may help patients with peripheral artery disease

Medicare details structure of new drug price negotiation program

Tocagen's brain cancer gene therapy trial continues. Investors worry

explore

Texas Department of Public Safety speaks out on migrant abuse allegations

Galapagos to make CAR

Divers poised to search for children washed away in Pennsylvania flash flood

Cherokee Nation medical school graduates its first class

Fertility clinic egg and embryo storage is a disaster

Novo Nordisk testing Wegovy against alcohol

knowledge

entertainment

focus

hotspot